“Stacking” means combining two or more peptides on a theory: each works through a different pathway, and together they add up to more growth hormone release than any one alone. For sermorelin, the two most commonly sold partners are CJC-1295 and ipamorelin. Clinics market the combination as an upgrade. What follows covers what each compound actually is, what evidence exists for combining them, and where the marketing runs ahead of what has been tested.
A separate sermorelin vs. ipamorelin comparison weighs those two compounds as single agents. What follows is about the combination pitch specifically — the claim that adding a second or third peptide changes what sermorelin alone can do.
What are sermorelin, CJC-1295 and ipamorelin?
Sermorelin is a 29-amino-acid analog of growth hormone-releasing hormone. It binds the GHRH receptor on the pituitary and prompts release of the body’s own growth hormone. Its adult human evidence rests on one 1997 trial (n = 19), covered in full in what sermorelin’s one adult trial found [1].
CJC-1295 is a modified, longer-acting version of that same GHRH(1-29) fragment. A 2005 paper by the company that developed it describes attaching a maleimide group that binds serum albumin, extending the molecule’s time in circulation. In the paper’s own language, the lead compound showed a 4-fold increase in GH area under the curve compared with unmodified GHRH(1-29), and it stayed detectable in blood beyond 72 hours [2]. That result came entirely from rats. A search of everything PubMed has indexed under CJC-1295 returns 33 records, mostly forensic and doping-detection chemistry, reviews of the broader peptide-drug landscape, and that original rat paper. Two of the 33 are human clinical trials, both published in 2006 in healthy adults, and both measured the same thing: how much growth hormone and IGF-1 the drug releases and for how long [4]. That is a biomarker result, not a body-composition or recovery result — the distinction this whole site keeps returning to. CJC-1295 has been shown to raise the marker. Nobody has published what happens downstream of it.
Ipamorelin is not a GHRH analog at all: it targets the ghrelin receptor (GHS-R), and its two human clinical trials studied bowel recovery after surgery and how the drug clears, not what it is sold for [5]. The premixed version sellers offer is covered in what a sermorelin and ipamorelin blend contains.
Why do clinics sell sermorelin stacks?
The rationale is not invented. A real synergy between a GHRH-receptor agonist and a ghrelin-receptor agonist has been measured directly in humans. A 2009 Mayo Clinic study infused GHRH and a ghrelin-mimetic peptide called GHRP-2 into 47 men, ages 18 to 74, at the same time (n = 47). The combination reliably produced a larger growth hormone pulse than either compound infused alone, a phenomenon the field calls GHRH-GHRP synergy. Its size varied with age, abdominal fat, and IGF-1 levels; together those three factors explained about 60% of the variation the researchers measured [3].
That is genuine, human-tested pharmacology. It is also a narrower finding than the marketing built on top of it. The study used intravenous infusion, for one test, measuring a single acute hormone pulse. It used GHRP-2, not ipamorelin. It used generic GHRH, not necessarily sermorelin or CJC-1295. None of that is the product being sold, dosed the way it’s sold, for the duration it’s sold. See how to read a peptide study for more on why that gap between a mechanism trial and a marketed product matters.
Has any sermorelin stack been tested?
Two direct searches answer this narrowly. “Sermorelin AND CJC-1295” together returns 14 PubMed records. “Sermorelin AND ipamorelin” together returns 5. Reading through both sets, a pattern repeats: recent reviews survey performance-enhancing and unapproved peptide drugs broadly, and doping-control chemistry papers describe methods for detecting these molecules in urine. The CJC-1295 set includes the original rat pharmacokinetics paper once more. Not one record in either search is a clinical trial of the combination itself, in any dose, in any population, for any duration [6].
No trial has tested a sermorelin–CJC-1295–ipamorelin stack, or any two-compound version of it, in a human being.
Two other pairings come up often. Some sellers combine sermorelin with the copper peptide GHK-Cu in a single tablet, covered in what the sermorelin GHK-Cu tablet contains, and some suggest adding MK-677, an oral pill that works through the same ghrelin receptor as ipamorelin; the sermorelin vs. MK-677 comparison sets the two side by side. For where all of these sit in the wider class, see the guide to growth hormone peptides, and before adding anything to a prescription, check what not to mix with sermorelin.
What does a stack ask you to assume?
Selling a stack means asking a buyer to accept several separate leaps, stacked on top of each other. First: that acute GHRH-GHRP synergy, shown with different peptides given by infusion to measure one hormone pulse, carries over to chronic subcutaneous dosing of the products actually sold. Second: that CJC-1295’s extended half-life, demonstrated in rats, produces a real clinical advantage in a person. Third: that combining these compounds outperforms what sermorelin alone showed in its own single human trial — lean mass in men, nothing in women, no measured effect on sleep, covered in the dose that trial actually used. A stack is marketed as an upgrade over evidence that is already thin on its own.
None of this means the underlying biology is fake. The receptor-level mechanism is real, and the acute synergy between the two pathways has been measured in an actual human trial. What has not been measured is simpler to state: whether combining these specific compounds, at the doses and duration actually sold, produces any outcome a person would notice over months of use.
What should a buyer make of stack pricing?
A seller charging more for a three-compound stack is often charging for two additional molecules with no dedicated human outcome data of their own, layered onto a base compound whose own adult evidence is a single, unreplicated trial from 1997. That framing does not settle whether a stack is worth its price. It describes what is and is not backed by a trial, so price and evidence can be weighed against each other honestly — the same distinction covered in how sermorelin marketing claims compare with the trial record.
Dosing compounds the problem. The synergy trial above used a single infused dose for a single overnight test, not a chronic regimen. No published study has established a dose-ranging schedule for sermorelin combined with CJC-1295 or ipamorelin, taken together, over weeks or months. A seller’s stack protocol is therefore not drawn from a tested regimen — it is drawn from clinical practice and extrapolation, the same gap that runs through sermorelin’s own marketed dose relative to the one trial that tested it.